tiprankstipranks
Celldex Therapeutics Inc (CLDX)
NASDAQ:CLDX

Celldex (CLDX) Income Statement

993 Followers

Celldex Income Statement

Last quarter (Q1 2024), Celldex's total revenue was $156.00K, a decrease of -83.87% from the same quarter last year. In Q1, Celldex's net income was $-32.81M. See Celldex’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 6.07M$ 6.88M$ 2.36M$ 4.65M$ 7.42M$ 3.57M
Cost of Revenue
$ 300.00K$ 300.00K$ 100.00K$ -100.00K--
Gross Profit
$ 6.07M$ 6.88M$ 2.36M$ 4.65M--
Operating Expense
$ 156.25M$ 148.93M$ 109.45M$ 73.80M$ 56.99M$ 58.10M
Operating Income
$ -162.68M$ -154.54M$ -115.23M$ -69.15M$ -49.57M$ -54.52M
Net Non Operating Interest Income Expense
$ 17.80M$ 13.11M$ 2.91M$ 505.00K--
Other Income Expense
$ -80.70M$ -80.50M$ -6.86M$ 2.10M$ -11.38M$ 3.65M
Pretax Income
$ -144.88M$ -141.43M$ -112.33M$ -70.74M$ -60.95M$ -50.88M
Tax Provision
$ -36.07M$ -36.07M$ -17.48M$ -227.00K$ -1.17M$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -144.88M$ -141.43M$ -112.33M$ -70.51M$ -59.78M$ -50.88M
Basic EPS
$ -2.86$ -2.92$ -2.40$ -1.64$ -2.02$ -3.51
Diluted EPS
$ -2.86$ -2.92$ -2.40$ -1.64$ -2.02$ -3.51
Basic Average Shares
$ 205.45K$ 48.45K$ 46.89K$ 42.87K$ 29.64M$ 14.51M
Diluted Average Shares
$ 205.45K$ 48.45K$ 46.89K$ 42.87K$ 29.64M$ 14.51M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 156.55M$ 149.22M$ 109.55M$ 73.70M$ 56.99M$ 58.10M
Net Income From Continuing And Discontinued Operation
$ -144.88M$ -141.43M$ -112.33M$ -70.51M$ -59.78M$ -50.88M
Normalized Income
$ -54.32M---$ -48.62M$ -54.52M
Interest Expense
------
EBIT
$ -144.50M$ -142.04M$ -112.33M$ -70.74M$ -49.57M$ -54.52M
EBITDA
$ -105.11M$ -139.03M$ -108.58M$ -70.88M$ -45.64M$ -49.67M
Currency in USD

Celldex Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis